<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180322</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 12-09</org_study_id>
    <nct_id>NCT01180322</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine</brief_title>
  <acronym>azacitidine</acronym>
  <official_title>Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II, four-arm, open-label, multi-center study in adult patients&#xD;
      with acute myeloid leukemia (AML) as defined in inclusion/exclusion criteria.&#xD;
&#xD;
      The primary efficacy objective is to evaluate the impact of sequential or concurrent addition&#xD;
      of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the&#xD;
      complete remission (CR) rate&#xD;
&#xD;
      Sample size: 336 patients&#xD;
&#xD;
      The treatment duration of an individual patient randomized into one of the three experimental&#xD;
      arms (Arm B, C, D) (in case of application of induction, consolidation and maintenance&#xD;
      therapy with Azacitidine) is about 30 months.&#xD;
&#xD;
      The treatment duration for patients randomized into the standard arm of the study (Arm A) is&#xD;
      about 7 months (in case of application of induction, consolidation and 2-yrs observation as&#xD;
      maintenance (without treatment with Azacitidine)).&#xD;
&#xD;
      In case of induction followed by consolidation with allogeneic Stem cell transplantation&#xD;
      (SCT) the treatment duration per patient is about 6 months.&#xD;
&#xD;
      Every patient will be followed until month 54 after inclusion into the study. Duration of the&#xD;
      study for an individual patient including treatment (induction, consolidation [chemotherapy&#xD;
      or allogeneic SCT], maintenance [experimental arm with Azacitidine or observation]) and&#xD;
      follow-up period: 54 months&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2, 2016</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of complete remission (CR) after induction therapy</measure>
    <time_frame>56 days</time_frame>
    <description>To evaluate the impact of sequential or concurrent addition of 5-azacytidine to intensive induction chemotherapy with idarubicin and etoposide on the CR rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>after two years of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>after two years of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>after two years of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days in hospital during each cycle and during the whole intervention</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early deaths or hypoplastic deaths (ED/HD)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 3.0), timing and relatedness of non-hematological toxicity observed during different treatment cycles</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30)</measure>
    <time_frame>at the end of therapy (in average 6 months) and once a year in the follow-up</time_frame>
    <description>quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics according to Messerer et al [35].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of leukopenia after each consolidation cycle</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of neutropenia after each consolidation cycle</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of thrombocytopenia after each consolidation cycle</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of leukopenia after each induction cycle</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of neutropenia after each induction cycle</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of thrombocytopenia after each induction cycle</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Therapy &quot;Azacitidine Prior&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Therapy &quot;Azacitidine Concurrent&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Therapy &quot;Azacitidine After&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)&#xD;
Consolidation therapy:&#xD;
Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).&#xD;
Elderly patients (&gt;65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>First induction therapy:&#xD;
Arm A, C, D:&#xD;
12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (&gt;65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.&#xD;
Arm B:&#xD;
12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (&gt;65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.&#xD;
Second induction therapy:&#xD;
Arm A, C, D:&#xD;
12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)&#xD;
Arm B:&#xD;
12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Induction therapy:&#xD;
Arm A, C, D:&#xD;
100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (&gt;65 yrs) patients only two doses of etoposide are foreseen on days 1+3.&#xD;
Arm B:&#xD;
100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (&gt;65 yrs) patients only two doses of etoposide are foreseen on days 6+8.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Induction therapy:&#xD;
Arm B and C:&#xD;
100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.&#xD;
Arm D:&#xD;
100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.&#xD;
Maintenance therapy:&#xD;
Arm B, C, D:&#xD;
50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenograstim</intervention_name>
    <description>Consolidation therapy:&#xD;
subcutaneously daily beginning on day 10 until neutrophil count &gt; 0.5 x 109/l.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected diagnosis of acute myeloid leukemia or related precursor&#xD;
             neoplasm, or acute leukemia of ambiguous lineage (classified according to the World&#xD;
             Health Organization (WHO) classification)&#xD;
&#xD;
          -  Patients considered eligible for intensive chemotherapy&#xD;
&#xD;
          -  WHO performance status of ≤ 2&#xD;
&#xD;
          -  Age ≥ 18 years. There is no upper age limit.&#xD;
&#xD;
          -  No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis&#xD;
&#xD;
          -  Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a&#xD;
             negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL&#xD;
             within 72 hours prior to registration. &quot;Women of childbearing potential&quot; is defined as&#xD;
             a sexually active mature woman who has not undergone a hysterectomy or who has had&#xD;
             menses at any time in the preceding 24 consecutive months.&#xD;
&#xD;
          -  Female patients in the reproductive age and male patients must agree to avoid getting&#xD;
             pregnant or to father a child while on therapy and for 3 month after the last dose of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Women of child-bearing potential must either commit to continued abstinence from&#xD;
             heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal&#xD;
             ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of&#xD;
             birth control.&#xD;
&#xD;
          -  Men must use a latex condom during any sexual contact with women of childbearing&#xD;
             potential, even if they have undergone a successful vasectomy. (while on therapy and&#xD;
             for 3 month after the last dose of chemotherapy)&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -AML with other recurrent genetic abnormalities (according to WHO 2008): AML with&#xD;
        t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);&#xD;
        CBFB-MYH11 AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA&#xD;
        gene fusions)&#xD;
&#xD;
          -  AML with NPM1 mutation&#xD;
&#xD;
          -  AML with FLT3 mutation&#xD;
&#xD;
          -  Performance status WHO &gt;2&#xD;
&#xD;
          -  Patients with ejection fraction &lt; 50% by Multi Gated Acquisition Scan (MUGA) or&#xD;
             echocardiogram (ECHO scan) within 14 days of day 1&#xD;
&#xD;
          -  Organ insufficiency (creatinine &gt;1.5x upper normal serum level; bilirubin, AST or ALP&#xD;
             &gt;2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV;&#xD;
             severe obstructive or restrictive ventilation disorder)&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Severe neurological or psychiatric disorder interfering with ability of giving an&#xD;
             informed consent&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers. Patients are not considered to have a &quot;currently active&quot; malignancy if they&#xD;
             have completed therapy and are considered by their physician to be at less than 30%&#xD;
             risk of relapse within one year.&#xD;
&#xD;
          -  Known positive for Human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Bleeding disorder independent of leukemia&#xD;
&#xD;
          -  No consent for registration, storage and processing of the individual&#xD;
             disease-characteristics and course as well as information of the family physician&#xD;
             and/or other physicians involved in the treatment of the patient about study&#xD;
             participation.&#xD;
&#xD;
          -  No consent for biobanking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard F Schlenk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabethinen Krankenhaus Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskliniken Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Evangelischs Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt-Höchst</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital Goch</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sklepios Klinik Hamburg-Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hanau</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRH Klinikum Hannover-Siloah</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes-Guttenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch-Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas-Klinik St. Theresia</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar-Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Richard Schlenk</investigator_full_name>
    <investigator_title>PD Dr.</investigator_title>
  </responsible_party>
  <keyword>azacitidine</keyword>
  <keyword>Acute myeloid Leukemia (AML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

